A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)

Trial Profile

A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs Abiraterone acetate (Primary) ; LHRH receptor agonists; Prednisone
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms LATITUDE
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 15 Feb 2018 Results published in a Janssen Media Release.
    • 15 Feb 2018 According to a Janssen media release, based on the data from this study, Health Canada's approval of ZYTIGA(abiraterone acetate) in combination with prednisone and androgen deprivation therapy (ADT) for the treatment of patients with newly diagnosed, high-risk metastatic hormone-sensitive prostate cancer (mHSPC) who may have received up to three months of prior ADT.
    • 13 Feb 2018 Results (n=70) from Japanese patients have been published in the Janssen Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top